MigVax Subunit COVID-19 Oral Vaccine Preclinical Trial Demonstrates Efficacy as a Booster


QIRYAT SHMONA, Israel – (COMMERCIAL THREAD) – MigVax Ltd., a start-up developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that have demonstrated the effectiveness of its oral subunit vaccine MigVax-101 as a booster for people previously vaccinated.

In the trial, tests in rats demonstrated that the oral subunit vaccine MigVax-101, when given as a booster after an injection of S1 protein, caused significantly higher neutralizing antibody titers. than rats given an oral placebo booster. In addition, similar to a third booster injection, it elicited more effective neutralizing antibodies.

MigVax is currently seeking funding to initiate Phase 1 and 2 clinical trials which, if successful, would lead to commercial availability 9 to 12 months after the start of the trials. For full preclinical test results, please refer here.

As an oral vaccine, Mig-Vax-101 offers significant potential advantages over current first generation injected vaccines:

  • Ease of administration: Oral administration avoids the need for administration by healthcare professionals.
  • Uniquely positioned to tackle new variants: The RBD subunit can be quickly adapted to new variants, an advantage that can help guide the production of more efficient neutralizing antibodies. In addition, since the other components of the vaccine consist of a protein which is not subject to change, the vaccine may remain effective longer before it needs a booster.
  • Mucosal immunity: Preclinical data demonstrated marked mucosal IgA in the lung lavage, which means that the oral vaccine offers special protection at the exact point needed: the port of entry of the virus.
  • Ease of transport and storage: Although the MigVax-101 requires refrigeration, it does not require “deep freeze” conditions. This significantly reduces the costs of distribution and storage and logistics.
  • Applicability to a wider population: Since the oral MigVax-101 subunit vaccine does not inject viruses or genetic material into people, it will be much more acceptable to a larger population, including those who are reluctant to receive injections of the material. genetic or viral as well as infants, children, pregnant women, women and certain other segments of the population.

“The results of this trial reinforce our confidence that our subunit oral vaccine MigVax-101 will make a positive contribution to a world facing the new post-pandemic reality,” commented Professor Itamar Shalit, expert in infectious diseases. by MigVax.

“Fifteen months after the start of the pandemic, we now see that the struggle to keep Covid under control is almost as difficult as getting it under control to begin with. Oral boosters such as our MigVax-101 will be key catalysts that will help healthcare organizations around the world move from “panic mode” to routine, due to their ability to reduce costs and expand the reach of health care programs. vaccination in progress. ”

MigVax-101 is a new oral subunit vaccine that uses a chimeric protein to generate three types of simultaneous immunological responses: mucosal, blood and cell-mediated immunity. This three-armed approach offers complete protection against infection by activating all arms of the immune system, allowing the effective eradication of the invading virus. Its epitopes were designed using the computational chemistry of immunogenic epitopes in IBV, MERS, SARS-COV and SAS-COV-2, with a focus on neutralizing antibodies and promoting an immune response.


About MigVax:
MigVax Ltd. is developing a new COVID-19 vaccine. MigVax, a subsidiary of Migal Galileo Research Institute. The Migal Galilee Research Institute previously developed a vaccine against the infectious bronchitis virus, a strain of coronavirus that causes bronchial disease affecting poultry. The vaccine’s efficacy against poultry has been proven in animal trials at the Israel Veterinary Institute. MigVax is using methods from the existing vaccine to develop a new human oral subunit vaccine against COVID-19. The first round of investment was led by Our Crowd a global venture capital investment platform that enables institutions and individuals to invest and engage in emerging companies.

For more information, please refer to http://www.migvax.com/ and https://www.migvax.com/copy-of-the-science , or contact:

View the source version on businesswire.com: https://www.businesswire.com/news/home/20210610005425/en/

Leave A Reply

Your email address will not be published.